Login to Your Account



Portola Ready to Fly Solo On Pivotal Betrixaban Trial

By Mari Serebrov
Washington Editor

Tuesday, November 22, 2011
Having raised $89 million in its latest financing round, Portola Pharmaceuticals Inc. is preparing to fly solo on its pivotal Phase III trial that will evaluate betrixaban in the prevention of pulmonary embolisms.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription